Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 20

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 20
---
 resources to prevent other companies from circumventing
or violating our intellectual property rights.

Intellectual property rights of third parties
could adversely affect our ability to commercialize our drug candidates, such that we could be required to litigate with or obtain licenses
from third parties in order to develop or market our drug candidates.

Our commercial success may
depend upon our future ability and the ability of our potential collaborators to develop, manufacture, market and sell our drug candidates
without infringing valid intellectual property rights of third parties.

If a third-party intellectual
property right exists it may require the pursuit of litigation or administrative proceedings to nullify or invalidate the third-party
intellectual property right concerned, or entry into a license agreement with the intellectual property right holder, which may not be
available on commercially reasonable terms, if at all.

Third-party intellectual property
right holders, including our competitors, may bring infringement claims against us. We may not be able to successfully settle or otherwise
resolve such infringement claims. If we are unable to successfully settle future claims or otherwise resolve such claims on terms acceptable
to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from, or experience
substantial delays in, marketing our drug candidate.

If we fail to settle or otherwise
resolve any such dispute, in addition to being forced to pay damages, we or our potential collaborators may be prohibited from commercializing
any drug candidates we may develop that are held to be infringing, for the duration of the patent term. We might, if possible, also be
forced to redesign our formulations so that we no longer infringe such third-party intellectual property rights. Any of these events,
even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise
be able to devote to our business.

Our reliance on third parties requires us
to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed

Because we collaborate with
various organizations and academic institutions on the advancement of our technology and drug candidates, we may, at times, share trade
secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable,
material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators,
advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit
the rights of the third